PFE
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Pfizer reported positive topline Phase 3 results for LITFULO in patients with nonsegmental vitiligoJul 31, 2026
- FDA grants Priority Review to Pfizer's TALZENNA plus XTANDI for metastatic prostate cancerJul 23, 2026
- FDA approved PADCEV plus Keytruda as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer regardless of cisplatin eligibilityJul 13, 2026
- Pfizer reported topline Phase 3 results for sigvotatug vedotin in previously treated metastatic non-squamous NSCLCJun 23, 2026
- FDA approved Pfizer's HYMPAVZI for two additional hemophilia patient populationsJun 8, 2026